Enadenotucirev

Drug Profile

Enadenotucirev

Alternative Names: Ad11/Ad3 chimeric group B adenovirus; ColoAd-1; EnAd; Oncolytic Ad11/Ad3 chimeric group B adenovirus

Latest Information Update: 09 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Merck & Co; PsiOxus Therapeutics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer
  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 07 Oct 2016 Full study efficacy and adverse events data from the phase I/II EVOLVE trial in Colorectal cancer, Non-small cell lung cancer, Bladder cancer and Renal cancer (Metastatic disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 30 Jun 2016 PsiOxus and Bristol-Myers Squibb agree to co-develop enadenotucirev for Solid tumours
  • 30 Jun 2016 PsiOxus plans a phase I trial for Solid tumours (Late stage disease, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top